Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESTIGE: Adjuvant Nivolumab + Ipilimumab in Resected Gastric Cancer
NCT03443856Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2019
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in gastric adenocarcinoma, esophagogastric junction adenocarcinoma (GEJA), sponsored by European Organisation for Research and Treatment of Cancer. Started Jul 2019; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
gastric adenocarcinomaesophagogastric junction adenocarcinoma (GEJA)
Beyond the preview
Go deeper on NCT03443856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443856.